Envisia Genomic Test Shows Promise in Differentiating IPF

Envisia Genomic Test Shows Promise in Differentiating IPF

294455

Envisia Genomic Test Shows Promise in Differentiating IPF

Veracyte has presented new data demonstrating the diagnostic performance and utility of its Envisia Genomic Classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs). The company is now planning to make the Envisia classifier available to international markets by the end of this year, enabling laboratories to perform the test locally. New findings reinforcing the test’s utility and solid diagnostic performance were presented across several abstracts at the American Thoracic…

You must be logged in to read/download the full post.